Most Promising Drugs in 2015
05 |
|
|
|
Olysio by Johnson & Johnson |
04 |
|
LCZ696 by Novartis |
Johnson & Johnson ( NYSE : JNJ ) recently won U . S . approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc .’ s Sovaldi , making it the second all-oral treatment available . The combination allows Olysio to be used without the standard therapies including interferon , an injection that sometimes has flu-like side effects .
www . jnj . com
When directly compared to standard treatment in heart failure patients , Novartis ’ ( NYSE : NVS ) LCZ696 reduced the risk of cardiovascular death by 20 percent . The drug has been given fast-track status by the FDA which is good news for the 5 million U . S . patients currently suffering from heart failure .
www . novartis . com
27